^
Association details:
Biomarker:No biomarker
Cancer:B Acute Lymphoblastic Leukemia
Drug:bortezomib (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/04/2022
Excerpt:
REGIMENS FOR RELAPSED OR REFRACTORY Ph-NEGATIVE T-ALL...Other Recommended Regimens...Bortezomib + chemotherapy…
Secondary therapy:
Chemotherapy